Women account for over 75% of Americans who experience migraines, which could be attributable to the way that estrogen levels affect cells in the brain, according to new study findings.
Women may be more susceptible to migraines and less responsive to migraine treatments due to the way that fluctuations in estrogen levels affect cells in the brain, according to new study findings.
More than 38 million people in the United States experience migraines, of whom over 75% are women. Women also experience migraines more frequently and severely and do not respond as well to treatments.
“Because women comprise over 75% of the migraineur population, female reproductive hormones, namely estrogen, are thought to play a crucial tole in this debilitating disease,” wrote the authors of the study. “Preclinical studies have demonstrated that estrogen increases susceptibility to an electrical phenomenon in the brain called cortical spreading depression, which is theorized to be associated with migraine with aura; however, its mechanism is unknown.”
The study is the first to assess the role of the sodium proton exchanger NHE1, which regulates the transport of protons and sodium ions across cell membranes. When there isn’t a high enough level of NHE1 or if there is a dysfunction, it can cause increased pain signaling, leading to a migraine. NHE1 issues can also affect the efficacy of migraine treatments, altering their ability to cross the blood-brain barrier.
Researcher examined both male and female rats, discovering that NHE1 expression levels were 4 times higher in the brains of male rats. In the female rats, higher estrogen levels corresponded with the lowest levels of NHE1 expression. There were no significant changes in NHE1 expression as testosterone levels varied, leading researchers to conclude that women are more susceptible to migraines because of their estrogen levels.
“Conducting research on the molecular mechanisms behind migraine is the first step in creating more targeted drugs to treat this condition, for men and women,” said Emily Galloway, undergraduate research assistant, department of pharmacology, University of Arizona, in a statement. “Knowledge gained from this work could lead to relief for millions of those who suffer from migraines and identify individuals who may have better response to specific therapies.”
Galloway presented the study findings during the 2018 Experimental Biology Meeting in San Diego, California.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Addressing Maternal Mortality in Medicaid by Focusing on Mental Health
February 15th 2023On this episode of Managed Care Cast, we speak with Inland Empire Health Plan, a managed care plan serving more than 1.4 million residents on Medi-Cal in California, about a new maternal mental health program aimed at supporting new mothers, both before they give birth and afterward.
Listen
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
What We’re Reading: Historic Low of Uninsured; Youth Gender Treatments; Birth Control Recall
August 4th 2023A record low of 7.7% of Americans had no health insurance at the start of 2023; the American Academy of Pediatrics renewed its backing of gender care for children while requesting a research review; 2 lots of an oral contraceptive were recalled for possible reduction in effectiveness.
Read More
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More